tirzepatide reviews side effects Mounjaro | Dealing With Side Effects Tirzepatide: Uses, Side Effects, Dosing,

Tirzepatide, a dual GIP and GLP-1 receptor agonist administered via subcutaneous injection, can cause localized injection site reactions in approximately 3-4% of patients

For SURMOUNT4, participants were to have reached their MTD dose by week 24, have no dose reduction by week 88, and have a weight measurement at week 88

Our team is here to support you every step of the way

However, SURPASS-CVOT demonstrated non-inferiority to dulaglutide for MACE-3, providing relevant clinical signals for patients with type 2 diabetes and established cardiovascular disease[2][3]

Not only for weight loss but also the reduction in cardiac death, heart attack and stroke

Patients currently on semaglutide who have hit a weight loss plateau often see renewed progress when transitioning to tirzepatide, likely due to the additional GIP receptor activation